Joel Diamond, MD, Co-Founder & Chief Medical Officer of Aranscia
Pharmacogenomics, also referred to as PGx, is the use of a patient’s genetic makeup to guide safer, more effective medication choices and dosing in everyday…
Continue Reading
David Talby, Ph.D., MBA, CEO of John Snow Labs
Doctors are taught a simple rule early in their training: When you hear hoofbeats, think horses, not zebras. In other words, the most common explanation is…
Continue Reading
Rare diseases (RD) affect 3.5–5.9% of the global population, yet patients often endure a diagnostic odyssey averaging around 5–6 years, navigating multiple specialties and referrals. This study investigates the use of information content (IC)…
Continue Reading
Rare diseases affect over 300 million people worldwide and pose unique research challenges. In silico approaches, such as mechanistic models, machine learning, and simulations, offer scalable tools for disease characterisation, drug discovery, and virtual…
Continue Reading
Understanding the Burden of Rare Diseases
Rare diseases represent a significant challenge for both patients and healthcare systems worldwide. Research demonstrates that the collective burden of rare diseases is comparable to that of major conditions…
What You Should Know:
– San Francisco-based Citizen Health, a platform empowering patients with rare and complex conditions, secures $30M in Series A funding led by 8VC, with participation from Transformation Capital and Headline, bringing…
Continue Reading
There are over 7000 rare diseases, some affecting 3500 or fewer patients in the United States. Due to clinicians’ limited experience with such diseases and the heterogeneity of clinical presentations, ~70% of individuals seeking…
Continue Reading
Pangea Data, a company focused on detecting rare diseases in patients, is partnering with Alexion, a subsidiary of AstraZeneca focused on treating rare diseases, to co-develop, clinically validate and ultimately seek regulatory approval for…
Continue Reading
Pangaea Data, a company focused on detecting hard-to-diagnose diseases in patients, is partnering with Alexion, a subsidiary of AstraZeneca focused on treating rare diseases, to co-develop, clinically validate and ultimately seek regulatory approval for an…
Continue Reading
Terry Ciesla, Senior Vice President at ScribeEMR, explains in this video how various AI scribes can be evaluated on the basis on how well they handle complex, obscure, and subtle details.He offers an example…
Continue Reading
